S100A9 Antibody

What is S100A9 and why is it significant in research?

S100A9 is a calcium-binding protein belonging to the S100 family that plays significant roles in inflammatory processes. It is expressed primarily in granulocytes and during early stages of monocyte differentiation . S100A9 often exists as a heterodimeric complex with S100A8 (known as S100A8/A9), and these complexes are expressed and released at inflammatory sites . The protein's significance stems from its role as a focal molecule in autoimmune disease regulation through interactions with proinflammatory mediators such as the receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4/MD2) . These interactions are dependent on both zinc and calcium ions, making S100A9 a promising therapeutic target, particularly in autoimmune and inflammatory conditions .

What are the key differences between monoclonal and polyclonal S100A9 antibodies?

Monoclonal S100A9 antibodies, such as the human S100A9 antibody (clone #474315), are derived from a single B-cell clone, recognizing a specific epitope on the S100A9 protein . They offer high specificity but limited epitope recognition. For example, the human monoclonal antibody effectively detects S100A9 in human PBMC, spleen, tonsil, and cartilage tissues at approximately 14 kDa .

In contrast, polyclonal S100A9 antibodies, like the goat anti-mouse S100A9, are produced from multiple B-cell clones and recognize multiple epitopes . The polyclonal antibody shows broader reactivity, with cited applications across human, mouse, and rat models . It demonstrates greater cross-reactivity (<2% with recombinant mouse S100A10 and human S100B) while maintaining effectiveness across multiple applications including immunohistochemistry in both frozen and paraffin sections .

The choice between these antibody types should be based on experimental needs: monoclonals for highly specific detection of a single epitope, and polyclonals for broader detection capability across multiple epitopes or species.

What cellular and tissue sources are optimal for S100A9 detection?

For human S100A9 detection, peripheral blood mononuclear cells (PBMCs) serve as excellent primary sources due to their high expression levels . Human spleen, tonsil, and cartilage tissues also provide reliable detection sources . The Capan-1 human pancreatic adenocarcinoma cell line has been validated for immunocytochemical detection of S100A9 .

For mouse S100A9 detection, lung tissue lysates provide strong signal detection at approximately 14 kDa under reducing conditions . The XB2 mouse teratoma keratinocyte cell line and mouse splenocytes are validated cellular models that show distinct localization patterns—S100A9 is detected in both cytoplasm and cell surfaces in splenocytes, making them particularly useful for studying surface expression that occurs during inflammation .

When selecting tissue sources, consider that S100A9 expression increases dramatically at inflammatory sites, making diseased or experimentally inflamed tissues potentially more informative than healthy controls for certain research questions .

What applications are S100A9 antibodies validated for?

Human S100A9 monoclonal antibodies have been validated for Western blot analysis using PVDF membranes with reducing conditions and specific immunoblot buffer systems . They have also been verified for immunocytochemistry in fixed cell lines, where they can be detected using appropriate fluorescent secondary antibodies followed by counterstaining with DAPI .

Mouse S100A9 polyclonal antibodies show broader application validation including:

• Western blot (under reducing conditions)

• Immunocytochemistry

• Immunohistochemistry (both frozen and paraffin-embedded sections)

• Simple Western assays

• Confocal microscopy

• ELISA development

• Functional assays

• Neutralization experiments

When implementing these applications, researchers should follow validated protocols that specify optimal antibody concentrations—for example, 0.5 μg/mL for Western blot analysis of human S100A9 and 10 μg/mL for immunocytochemistry . Similarly, for mouse S100A9 detection, 0.2 μg/mL is recommended for Western blot and 5-10 μg/mL for immunostaining techniques .

How do divalent cations affect S100A9 antibody binding and experimental design?

The interaction of S100A9 with its binding partners—including antibodies—is critically dependent on both zinc (Zn++) and calcium (Ca++) ions . This dependency creates important considerations for experimental design:

When designing binding studies, buffer composition must include appropriate concentrations of both Ca++ and Zn++ to maintain proper protein conformation. The absence of either ion can significantly alter experimental outcomes, particularly in binding assays, surface plasmon resonance (SPR) experiments, and functional studies .

Researchers should implement a systematic approach to divalent cation concentration optimization:

• Include titration series of both Zn++ and Ca++ in preliminary experiments

• Use appropriate chelators (EDTA or EGTA) as negative controls to confirm cation-dependent binding

• Consider that physiological fluxes in cation concentrations may create artifacts in ex vivo systems

For antibodies targeting conformational epitopes, special attention should be paid to maintaining cation concentrations throughout fixation and sample preparation procedures, as these epitopes may be disrupted by standard processing methods that deplete divalent cations .

What are the critical considerations when targeting S100A9 in autoimmune disease models?

When investigating S100A9 in autoimmune disease models, researchers should consider several complexities revealed by recent studies:

First, the relationship between S100A9 and disease severity is counterintuitive in some models. S100A9-/- mice paradoxically showed more severe disease in experimental autoimmune encephalomyelitis (EAE) despite S100A9's proinflammatory role, suggesting compensatory mechanisms or redundancy in the inflammatory cascade . This highlights the importance of complementary approaches beyond simple gene deletion.

Second, the functional differences between S100A9 homodimers versus S100A8/A9 heterodimers are significant. Binding assays revealed that homodimeric S100A9 shows stronger interaction with quinoline-3-carboxamides compared to the heterodimeric complex, suggesting different biological functions that should be distinguished in experimental designs .

Third, S100A9's dual receptor interactions (with both RAGE and TLR4/MD2) require careful consideration when designing blocking experiments or therapeutic interventions . Researchers should determine which pathway predominates in their specific disease model, as this may vary between different autoimmune conditions.

Finally, when developing therapeutic approaches targeting S100A9, structure-activity relationship (SAR) studies are essential, as demonstrated by the correlation between quinoline-3-carboxamide binding strength to S100A9 and their potency in inhibiting autoimmune disease .

How can S100A9 antibodies be optimized for distinguishing between monomeric, homodimeric, and heterodimeric (S100A8/A9) forms?

Distinguishing between different oligomeric forms of S100A9 presents a significant technical challenge requiring careful antibody selection and experimental design:

For Western blot applications, sample preparation conditions critically influence the detection of different forms. Non-reducing conditions preserve disulfide bonds that may stabilize specific oligomeric states, while reducing conditions typically detect the monomeric 14 kDa form of S100A9 . Consider running parallel samples under both conditions to identify oligomeric states.

Epitope selection is crucial for developing antibodies that preferentially recognize specific forms. Targeting epitopes at protein-protein interfaces can generate antibodies that specifically recognize either the homodimeric or heterodimeric forms. Validation of such antibodies should include:

• Surface plasmon resonance comparing binding kinetics to purified monomeric, homodimeric, and heterodimeric forms

• Competitive binding assays using known form-specific ligands

• Immunoprecipitation followed by mass spectrometry to confirm captured forms

Native gel electrophoresis combined with Western blotting provides a powerful approach for distinguishing between oligomeric states while maintaining their native conformations. This approach revealed that binding of quinoline-3-carboxamides was primarily restricted to homodimeric S100A9, with only weak binding to S100A8/A9 heterocomplexes .

Researchers should also consider divalent cation concentrations, as Ca++ and Zn++ affect the equilibrium between different oligomeric forms, potentially confounding experimental interpretations if not carefully controlled .

What methodological approaches can resolve contradictory findings in S100A9 knockout studies?

The unexpected finding that S100A9-/- mice exhibited more severe EAE disease despite S100A9's proinflammatory properties highlights the complex nature of S100A9 biology and the need for sophisticated methodological approaches . To resolve such contradictions, researchers should consider:

Compensatory mechanism analysis: Perform transcriptomic and proteomic profiling of tissues from S100A9-/- mice to identify upregulated proteins that might compensate for S100A9 loss. Special attention should be paid to other S100 family members, given that S100A8-/- mice are embryonically lethal while S100A9-/- mice are viable, suggesting complex interdependencies .

Temporal knockout strategies: Employ inducible knockout systems to delete S100A9 at different disease stages, distinguishing between developmental compensation and acute functional requirements. This approach can help resolve why constitutive knockout phenotypes may differ from antibody neutralization or pharmacological inhibition results.

Cell-specific knockouts: Generate conditional knockouts restricting S100A9 deletion to specific cell populations (e.g., granulocytes vs. monocytes) to delineate cell-specific contributions to disease pathogenesis.

Cross-species considerations: Account for species differences in the S100 family. For example, S100A12 functions as a RAGE ligand in humans but is absent in the mouse genome . Human and mouse data should be reconciled through parallel studies in both systems where possible.

Combined approaches: Implement multiple inhibition strategies simultaneously (genetic knockout, neutralizing antibodies, and small molecule inhibitors) to comprehensively assess S100A9's role and identify possible discrepancies between approaches.

What are the optimal conditions for Western blot detection of S100A9?

Successful Western blot detection of S100A9 requires careful optimization of several parameters:

Membrane selection: PVDF membranes have been validated for both human and mouse S100A9 detection . Nitrocellulose alternatives should be empirically tested if used.

Buffer systems: For human S100A9, Immunoblot Buffer Group 1 under reducing conditions yields optimal results . Mouse S100A9 detection has also been validated under reducing conditions . The specific reducing agent (DTT vs. β-mercaptoethanol) should be selected based on preliminary optimization experiments.

Antibody concentrations: For human S100A9, 0.5 μg/mL of monoclonal antibody produces clear detection . For mouse S100A9, 0.2 μg/mL of polyclonal antibody is recommended . Titration experiments should be performed for each new tissue source or lot of antibody.

Expected molecular weight: Both human and mouse S100A9 appear at approximately 14 kDa under reducing conditions . Higher molecular weight bands may indicate oligomeric forms or post-translational modifications.

Sample preparation considerations:

• Include protease inhibitors in lysis buffers to prevent degradation

• Standardize protein loading (typically 20-50 μg total protein per lane)

• Consider native conditions when oligomeric state determination is important

• Include positive control lysates (PBMC for human, lung tissue for mouse)

Secondary antibody selection: For mouse monoclonal primary antibodies, HRP-conjugated anti-mouse IgG secondary antibodies have been validated . For goat polyclonal primaries, HRP-conjugated anti-goat IgG secondaries are recommended .

How can researchers troubleshoot inconsistent S100A9 immunostaining results?

Inconsistent immunostaining results can stem from multiple factors. A systematic troubleshooting approach should include:

Fixation optimization:
S100A9 detection is sensitive to fixation conditions. For cell lines, immersion fixation has been validated for both human and mouse S100A9 detection . Test multiple fixation protocols (paraformaldehyde, methanol, acetone) to determine optimal conditions for your specific sample type.

Epitope masking and retrieval considerations:
Calcium-binding proteins like S100A9 may undergo conformational changes during fixation. If signal is weak:

• Implement antigen retrieval methods (citrate buffer, pH 6.0 or EDTA buffer, pH 9.0)

• Titrate retrieval time and temperature

• Consider the impact of divalent cation chelation on epitope accessibility

• Sample type (cell line vs. tissue section)

• Fixation method

• Detection system

• Storage time of fixed samples

Background reduction strategies:
If high background is observed:

• Increase blocking time/concentration

• Use species-specific serum matching the host of your secondary antibody

• Include 0.1-0.3% Triton X-100 for intracellular staining

• Consider autofluorescence quenching for tissues with high endogenous fluorescence

Signal amplification options:
For weak signals, consider:

• Tyramide signal amplification systems

• Polymer-based detection methods

• Fluorophores with higher quantum yield

• Confocal microscopy with spectral unmixing for samples with autofluorescence

Counterstain considerations:
DAPI has been validated as a nuclear counterstain for S100A9 immunocytochemistry . When implementing multi-color staining, consider fluorophore spectral overlap and appropriate controls.

What experimental controls are essential when studying S100A9 in inflammatory conditions?

Robust experimental design for S100A9 studies in inflammatory conditions requires comprehensive controls:

Antibody specificity controls:

• Isotype controls matching the primary antibody species, isotype, and concentration

• Antigen pre-absorption controls using recombinant S100A9

• S100A9-/- tissues or cells when available

• Western blot validation of antibody specificity in the specific tissue being studied

S100A8/A9 heterodimer vs. S100A9 homodimer controls:

• Parallel staining with S100A8-specific antibodies

• Co-immunoprecipitation followed by Western blot to confirm oligomeric state

• Binding competition assays with known form-specific ligands

Calcium and zinc dependency controls:

• Chelation controls using EDTA (for both Ca++ and Zn++) or EGTA (Ca++-specific)

• Supplementation experiments with exogenous Ca++ and Zn++ at varying concentrations

• Calcium ionophore treatment to assess calcium-dependent conformational changes

Inflammatory state normalization:

• Time-course experiments to track S100A9 expression during inflammation progression

• Parallel measurement of established inflammatory markers (IL-6, TNF-α, CRP)

• Cell-type specific markers to identify S100A9-expressing populations

• Quantification of neutrophil and monocyte infiltration

Functional validation controls:

• Neutralizing antibody experiments targeting S100A9

• Quinoline-3-carboxamide compounds as validated S100A9 inhibitors

• siRNA knockdown or CRISPR-mediated deletion in cell culture systems

• Binding partners blocking (anti-RAGE or anti-TLR4 antibodies) to confirm pathway-specific effects

How does post-translational modification affect S100A9 detection and function?

S100A9 undergoes various post-translational modifications (PTMs) that significantly impact its detection and biological activity:

Oxidative modifications:
S100A9 contains redox-sensitive residues that undergo oxidation during inflammatory conditions. These modifications can alter epitope recognition by antibodies and change functional interactions with receptors like RAGE and TLR4 . Researchers should:

• Compare reducing and non-reducing conditions in Western blot analyses

• Consider antioxidant addition during sample preparation to preserve native state

• Use redox-insensitive epitopes for antibody development when possible

Calcium and zinc binding:
These divalent cations induce conformational changes that expose hydrophobic regions necessary for receptor binding . Experimental considerations include:

• Maintaining physiological calcium and zinc concentrations during sample preparation

• Using chelation-resistant fixation methods for immunohistochemistry

• Developing conformation-specific antibodies that recognize the calcium/zinc-bound state

Phosphorylation:
S100A9 phosphorylation occurs during neutrophil activation and affects its biological functions. To account for phosphorylation states:

• Use phospho-specific antibodies when studying activated neutrophils

• Implement phosphatase inhibitors during sample preparation

• Consider lambda phosphatase treatment as a control

S100A9 detection across different PTM states:
To comprehensively profile S100A9 PTMs:

• Employ 2D gel electrophoresis to separate PTM variants

• Use mass spectrometry to identify specific modifications

• Develop PTM-specific antibodies for particular research questions

• Consider the tissue and disease context, as PTM patterns vary by inflammatory condition

When interpreting functional studies, researchers should recognize that specific PTMs may enhance or inhibit S100A9's interactions with RAGE or TLR4/MD2, potentially explaining contradictory results observed across different experimental systems .

How can S100A9 antibodies be used to validate therapeutic targeting strategies?

S100A9 antibodies serve as critical tools for validating therapeutic approaches targeting this protein in inflammatory and autoimmune diseases:

Target engagement verification:
Antibodies can confirm binding of therapeutic compounds to S100A9. For quinoline-3-carboxamides, competition assays with S100A9 antibodies targeting the compound-binding domain help establish mechanism of action . Researchers should:

• Develop domain-specific antibodies targeting the quinoline-3-carboxamide binding region

• Perform competitive binding assays between therapeutic compounds and antibodies

• Use these antibodies as positive controls in target engagement studies

Pharmacodynamic biomarker development:
S100A9 antibodies enable monitoring of target modulation during treatment. Methods include:

• Flow cytometry to measure cell-surface S100A9 expression on circulating monocytes

• Immunohistochemistry to assess tissue infiltration by S100A9-positive cells

• ELISA measurement of S100A8/A9 complex levels in serum or tissue

• Proximity ligation assays to detect S100A9 interactions with RAGE or TLR4/MD2

Structure-activity relationship (SAR) studies:
S100A9 antibodies have revealed important correlations between compound binding to S100A9 and therapeutic efficacy. This approach demonstrated that the potency of quinoline-3-carboxamides in inhibiting experimental autoimmune encephalomyelitis correlates with their binding strength to S100A9 . Researchers should:

• Characterize binding affinities using surface plasmon resonance

• Correlate binding parameters with in vivo efficacy measures

• Use competitive antibody binding to map compound interaction sites

Mechanism differentiation:
S100A9 antibodies help distinguish between different mechanisms of therapeutic action:

• Receptor blocking (RAGE vs. TLR4/MD2)

• Oligomerization inhibition

• Cell surface expression modulation

• Direct neutralization of S100A9

Each mechanism may be appropriate for different disease contexts, requiring tailored antibody-based validation strategies .